Yahoo · Oct 30, 2026
Why Did Insmed Stock Jump?
For questions about this article or underlying research, email [email protected].
SV
NASDAQ · SVRA
Savara Inc.
Healthcare · Biotechnology
$4.75
Down-$0.09 (-1.89%)
Updated Nov 4, 2026, 9:42 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.41B
- P/E ratio
- -13.6
- Dividend yield
- 0.00%
- 52-week range
- $4.13 – $6.48
- Volume
- 2.12M
- Avg. volume
- 1.96M
Price performance · SVRA
SVRA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SVRA closed at $4.75 after 21 trading sessions, up 2.15% for the selected period.
- Last close
- $4.75
- Period change
- +2.15%
- Period low
- $4.22
- Period high
- $5.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $4.78 | $4.88 | $4.655 | $4.75 | 2.12M |
| Nov 2, 2026 | $4.83 | $4.91 | $4.67 | $4.73 | 1.78M |
| Oct 30, 2026 | $4.88 | $4.97 | $4.7498 | $4.82 | 1.41M |
| Oct 29, 2026 | $5.05 | $5.135 | $4.915 | $4.95 | 1.74M |
| Oct 28, 2026 | $4.82 | $5.05 | $4.775 | $5.02 | 1.79M |
| Oct 27, 2026 | $4.49 | $4.905 | $4.45 | $4.86 | 3.59M |
| Oct 26, 2026 | $4.335 | $4.54 | $4.216 | $4.52 | 3.45M |
| Oct 23, 2026 | $4.52 | $4.58 | $4.13 | $4.22 | 2.83M |
| Oct 22, 2026 | $4.65 | $4.75 | $4.45 | $4.54 | 2.71M |
| Oct 21, 2026 | $4.79 | $4.945 | $4.66 | $4.67 | 2.09M |
| Oct 20, 2026 | $4.64 | $4.99 | $4.60 | $4.76 | 4.42M |
| Oct 19, 2026 | $4.53 | $4.705 | $4.495 | $4.63 | 1.56M |
| Oct 16, 2026 | $4.75 | $4.77 | $4.44 | $4.45 | 2.24M |
| Oct 15, 2026 | $4.76 | $4.90 | $4.72 | $4.74 | 1.69M |
| Oct 14, 2026 | $4.71 | $4.82 | $4.65 | $4.76 | 2.57M |
| Oct 13, 2026 | $4.84 | $5.02 | $4.76 | $4.78 | 3.74M |
| Oct 12, 2026 | $4.93 | $5.00 | $4.81 | $4.84 | 1.31M |
| Oct 9, 2026 | $4.82 | $4.975 | $4.81 | $4.92 | 1.53M |
| Oct 8, 2026 | $4.85 | $4.92 | $4.635 | $4.83 | 2.52M |
| Oct 7, 2026 | $4.74 | $5.05 | $4.69 | $4.88 | 2.42M |
| Oct 6, 2026 | $4.82 | $4.84 | $4.60 | $4.65 | 2.29M |
Latest SVRA news
The latest Smart Investors Daily articles mentioning SVRA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SVRA research
Overview
Company profile and research snapshot.
Company profile
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | JP Morgan | Overweight | — |
| Dec 23, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2025 | Wells Fargo | Overweight | — |
| Nov 14, 2025 | Oppenheimer | Outperform | — |
| Nov 13, 2025 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a post-hoc analysis of the IMPALA clinical trial evaluating the effects of molgramostim in aPAP patients with mildly decreased or normal diffusion capacity, defined as a baseline percent predicted hemoglobin-adjusted diffusing capacity of the lungs for
Benzinga · Oct 21, 2026
Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a
Yahoo · Oct 13, 2026
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
Savara Inc. announced that CHEST 2026 accepted an encore oral presentation on Phase 3 IMPALA-2 data and a poster on Phase 2/3 IMPALA molgramostim data in autoimmune pulmonary alveolar proteinosis, both to be presented in Phoenix, Arizona, on October 18–21, 2026. The focus on long-term efficacy and safety, plus outcomes in patients with mild diffusion impairment, highlights how comprehensively molgramostim is being evaluated for autoimmune pulmonary alveolar proteinosis. With this fresh focus...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
